Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

Financial Strength

8/10

Name	Current	Vs Industry
Cash-To-Debt	551.41
Equity-to-Asset	0.64
Debt-to-EBITDA	-0.01
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	6.69	Distress Grey Safe
Beneish M-Score	-2.04	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	47.5
	3-Year EBITDA Growth Rate	1
	3-Year EPS without NRI Growth Rate	3.8
	3-Year FCF Growth Rate	-34
	3-Year Book Growth Rate	7.6
	Future 3-5Y Total Revenue Growth Rate	-9.81

Momentum Rank

3/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	49.3
	9-Day RSI	53.41
	14-Day RSI	54.68
	6-1 Month Momentum %	333.33
	12-1 Month Momentum %	639.52

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	12.82
	Quick Ratio	12.82
	Cash Ratio	10.78
	Days Sales Outstanding	63.03
	Days Payable	455.61

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-12.6
	Shareholder Yield %	-13.89

Profitability Rank

1/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	69.8
	Operating Margin %	-156.68
	Net Margin %	-131.73
	FCF Margin %	-148.22
	ROE %	-91.84
	ROA %	-30.6
	ROIC %	-132.52
	ROC (Joel Greenblatt) %	-1439.76
	ROCE %	-41.43

GF Value Rank

1/10

	Name	Current	Vs Industry		Vs History
	PS Ratio	29.89
	PB Ratio	7.41
	Price-to-Tangible-Book	7.97
	EV-to-EBIT	-20.89
	EV-to-EBITDA	-21.15
	EV-to-Forward-EBITDA	-16.99
	EV-to-Revenue	31.61
	EV-to-Forward-Revenue	29.7
	EV-to-FCF	-21.33
	Price-to-Net-Current-Asset-Value	8.29
	Price-to-Net-Cash	11.16
	Earnings Yield (Greenblatt) %	-4.79
	FCF Yield %	-4.22

GF Value: $3.96

SLNCF

Warning Signs

Warning! GuruFocus detected 3 Good signs with SLNCF. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.